Mitchel L. Zoler, PhD March 14, 2023 NEW ORLEANS – An investigational, first-in-class agent that delivers a completely new type of intervention to patients with pulmonary arterial hypertension (PAH) scored a clear win in the STELLAR trial, the first to complete among three phase 3 trials that are testing this agent. Sotatercept, administered subcutaneously every 3 weeks for 24...